RESEARCH & COURSES
We provide full training in Hong Kong for applying bioresonance according to Paul Schmidt. Owners of Polar and PS10 devices will be equipped to use Rayonex devices for testing and harmonising oneself, other people or animals. Training will include use of the Rayotensor, principles and methods for testing foods and substances, methods for alleviating allergies, and introduction to RAH programs for various conditions. Please contact us here for an appointment.
Students and users of bioresonance according to Paul Schmidt are invited to attend a 5-day training course at Rayonex headquarters in Lennestadt, Germany, or at a training centre in London. The courses are taught in English and are designed to provide a valuable immersion experience. A team of 14 bioresonance experts led by Prof. Dietmar Heimes meticulously developed the 5-day course to provide an overview of the theory and application of bioresonance.
During the 5 days, two international trainers will guide students through15 modules that cover basic fundamentals and advanced application of bioresonance testing and harmonisation. On the final day, a 45-minute exam will be given. Those who pass the exam will be awarded a certificate as a Certified Practitioner of Bioresonance according to Paul Schmidt.
The course is open to all. Prior knowledge of bioresonance is not required. Polar and PS10 devices with accessories are provided together with extensive course materials. Courses will start each morning at 9:00am, followed by a lunch break from 12:45-1:45pm, and end around 5:30pm.
The course fee for Germany is the HKD equivalent of 1,487.50 Euros, including 6 nights accommodation with breakfast and lunch. Lunch will be served in the Galileo-Park of the Sauerland Pyramids. Transfers by coach to and from Frankfurt airport will be provided before the start and at the end of the course by prior arrangement.
The course fee for London is the HKD equivalent of £1,795 (British Pounds), including 6 nights accommodation with breakfast. The training centre and accommodation hotels are just several minutes' drive from Heathrow Airport in London.
Due to the Covid situation, course dates for 2021 have not been determined.
If you are interested in enrolling in a 5-day course in Lennestadt or London when courses become available, please contact us here and we will keep you updated on developments.
Students interested in using bioresonance according to Paul Schmidt for animals are invited to attend a 3-day training course at Rayonex headquarters in Lennestadt, Germany. The course will be taught in English and will provide a valuable immersion experience for learning theory and practice.
During the 3 days, two international trainers will guide a maximum of 16 students through12 modules that cover fundamentals and practice in the application of bioresonance for animals. On the final day a 45-minute written exam will be given, followed by a 2-hour practical exam in a horse stable. Those who pass the exam will be awarded a certificate as a Certified Bioresonance Vet Practitioner according to Paul Schmidt.
The course is open to all. Prior knowledge of bioresonance is not required but basic skills in using the Rayotensor will be helpful. Polar and PS10 devices and accessories are provided together with extensive course materials. Courses will start each morning at 9:00am, followed by a lunch break between 12:45-1:45pm, and end around 5:30pm.
The course fee is the HKD equivalent of 893 Euros, including 3 nights accommodation with breakfast and lunch. Lunch will be served in the Galileo-Park of the Sauerland Pyramids. Transfers by coach to and from Frankfurt airport will be provided before the start and at the end of the course by prior arrangement.
Due to the Covid situation, course dates for 2021 have not been determined.
If you are interested in enrolling in a 3-day Vet course in Lennestadt when courses become available, please contact us here and we will keep you updated on developments.
The effectiveness of Rayonex bioresonance devices has been the subject of a number of studies, including the 2019 double-blind, randomised controlled study that gave the most scientific proof. The study involved patients with cervical spine syndrome (CSS), a pain condition that affects some 20% of the population. The study of 54 patients, half assigned to the treatment group and half the placebo control group, was aimed at determining whether bioresonance treatments by Rayonex’s Polar 4.0 medical devices could reduce pain and increase mobility for the patients. All patients in the study had at least moderate pain in the cervical spine region for over 3 years.
Cervical spine syndrome has relatively non-specific symptoms.It can cause pain, dysfunction and nerve irritation in the neck, shoulders, arms and joints. These may be followed by headaches, dizziness, visual disorders and tinnitus.
After 10 weeks, patients who received weekly treatments (130 minutes each time) from a Polar 4.0 reported significant improvements in neck pain, headaches, back pain, shoulder pain or muscle tension. Those in the control group who received placebo treatments reported no significant improvements.
In terms of physical capacity, patients in the treatment group reported significant improvements in parameters including sports, hiking, housework, gardening, swimming, biking, everyday life and social activities.Those in the placebo control group reported no significant improvements in the same activities.
In terms of pain, vitality, general health perceptions, physical functioning, social functioning, emotional health and mental health, treatment patients reported significant improvements in all aspects. Those in the control group reported no significant improvements.
In sum, the group that received bioresonance treatments achieved significant improvements in all objective and subjective parameters compared to the control group.
The results from study - considered to be the “gold standard” of epidemiological studies as it provides the strongest possible scientific evidence - support positive findings from previous studies as well as testimonials by therapists and patients over many years.
In the CSS study, subjects were assigned at random to intervention (in this case Polar 4.0 bioresonance treatment) and placebo control (in this case inactivated devices which provide the appearance of treatments but produce no effect). Neither the subjects nor the investigators knew who were receiving real treatments. This was supposed to eliminate any subjective, “placebo” feeling of benefit due to a belief in treatments. Participants would also be deterred from over-zealous reporting of positive results since they did not know whether they were in the treatment group or the control group.
For this study, the participants were 17 men and 37 women aged between 28 and 84. They were recruited for the specific purpose of testing the efficacy of the Rayonex bioresonance device for treating CSS. The inclusion criteria included age (at least 18), pain in the cervical spine region of at least a moderate degree on a “neck disability index”, ability and willingness to answer questionnaires, and willingness to provide written informed consent.
All the patients confirmed that they had been diagnosed with CSS for at least 3 years, and agreed to be assessed by way of a Neck Disability Index and a Visual Analogue Scale before and and after treatments. The Neck Disability Index is an established, validated measuring instrument for quantifying the pain caused by CSS. The Visual Analogue Scale has been used to record pain intensity as an indicator of significant symptoms.
Both treatment and placebo groups had a similar proportion of patients with various pre-existing medical conditions typical of population samples. All patients continued with their pre-existing medication regime as well as their customary diet and lifestyle.
The study had exclusion criteria encompassing life-threatening diseases, inflammatory musculoskeletal diseases, trauma from fractures and surgeries, severe degenerative diseases with significant restricted movements, pregnant or breast-feeding women, mental illnesses, alcohol or drug abuse, incapacitation, incarceration, people employed by or were dependent on the sponsor or investigator, and people taking part in another study.
The Lower Saxony ethics committee voted in favour of carrying out the study after determining that there were no ethics issues.
The study lasted 12 weeks including interviews. The first patient was included on 27/05/2019 and the last patient finished participating on 12/11/2019. During the study there were 7 patients who dropped out due to various personal reasons. The final numbers were thus 24 in the treatment group and 23 in the placebo group, making a total of 47.
In the final clinical report of Feb 2020, titled “Randomised, prospective, double-blind study to provide objective proof of the performance and safety of the Rayocomp bioresonance device in patients with cervical spine syndrome”, the author Dr Hans Werner gave the following conclusion:
“The Rayocomp PS 1000 Polar 4.0 bioresonance device achieved significant improvements in all objective and subjective parameters compared to the placebo device. This study is particularly important as it adopts a double-blind design involving a placebo device for comparison."
“Furthermore, the study confirms that the Rayocomp PS 1000 Polar 4.0 bioresonance device is safe.... No adverse effects were detected during this clinical trial that could alter the risk profile of the Rayocomp PS 1000 Polar 4.0 bioresonance device. The favourable safety profile of the medical device was confirmed.”
The full report of this study is available here.
A 2014 study of the bioresonance effect of the Mini-Rayonex (“Mini”) on cell cultures was done by Dartsch Scientific GmbH (Institute of Cell Biological Test Systems). The in vitro study showed that cell metabolism was stimulated by 45% after cell cultures were exposed for 24 hours to the Mini, compared to cell cultures not exposed to the Mini. Wound healing was sped up by 20% after 3 days exposure to the Mini, compared with cell cultures not exposed to the Mini. A full report in English is available here.
Below is a one-minute time-lapsed video on wound healing with and without a Mini from the same experiment.
On the left side of the time-lapse video, the healing process of cells on a strip with precisely defined width is shown WITHOUT the influence of the Mini-Rayonex. On the right side of the video, the process is shown WITH the influence of the Mini-Rayonex. It can clearly be seen that with the influence of the Mini-Rayonex, the wound heals up more quickly. This visual illustration is backed up by multiple laboratory tests showing the Mini-Rayonex had sped up wound-healing by up to 20%.
A 2011 efficacy study of the Polar and the PS10, using 7,000 cell cultures of human fibroblasts and keratinocytes, was done by the Fraunhofer Institute in Dresden. Results showed bioresonance treatments increased metabolic activity of fibroblasts by up to 8%, and increased wound-healing cell division activity of damaged cells by 40%. A further finding was that there were no morphological changes to all the treated cells, showing that influence from the devices did not cause any side effects. A summary report in English is available here.
A 2011 study of the Polar’s effectiveness in pain relief was conducted by Dr Axel Schußmann and Dr Karin Schußmann, who published a report of 30 cases. After an average of 12.4 Polar treatments, each between 20-45 minutes, over an average of 32 days, the patients with various pain symptoms reported overall improvement in pain relief. The average starting pain score of 7.8 on a scale of 1-10 dropped to 4.4 at the end of the treatment period, and dropped further to an average of 2.5 in follow-up visits after an average of 38 days. A full report in English is available here.